Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-HTTLPR in delusional and nondelusional depression

Biological Psychiatry

Volumn 50, Issue 5, 2001, Pages 323-330

  Zanardi, Raffaella ^a,b   Serretti, Alessandro ^a   Rossini, David ^a   Franchini, Linda ^a   Cusin, Cristina ^a   Lattuada, Enrico ^a   Dotoli, Danilo ^a   Smeraldi, Enrico ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Depression; Fluvoxamine; Pharmacogenetics; Pindolol; Serotonin transporter; Treatment response

Indexed keywords

FLUVOXAMINE; PINDOLOL; PLACEBO; SEROTONIN TRANSPORTER;

ADULT; ALLELE; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELUSION; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; FEMALE; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REDUCTION; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CARRIER PROTEINS; DELUSIONS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; GENOTYPE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PINDOLOL; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 0035450812     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(01)01118-0     Document Type: Article

References (77)

1. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode
2. Practice guideline for major depressive disorder in adults
3. Practice guideline for the treatment of patients with bipolar disorder
4. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors
5. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists
6. Genetic population structure of Italy. I. Geographic patterns of gene frequencies
7. Scales for assessment of diagnosis and severity of mental disorders
8. A comparison between delusional and non-delusional depressives
9. Serotonin transporter gene and manic depressive illness: An association study
10. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression
11. The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial
12. Progress and pitfalls: Bipolar molecular linkage studies
13. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression
14. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d'Experimentation Psychopharmacologique
15. Validity of subtyping psychotic depression: Examination of phenomenology and demographic characteristics
16. Primary and secondary affective disorder: Part III. Longitudinal differences in depression symptoms
17. Variability in treatment-seeking cocaine abusers: Implications for clinical pharmacotherapy trials
18. Lithium-responsive affective disorders: No association with the tyrosine hydroxylase gene
19. Delusional and nondelusional unipolar depression: Further evidence for distinct subtypes
20. Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program
21. Serotonin transporter (5-HTT) gene and bipolar affective disorder
22. A functional variant of the serotonin transporter gene in families with bipolar affective disorder
23. Psichotic depression: A separate entity?
24. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees
25. PI, GC, HP, and TF serum protein polymorphisms in Siena, Tuscany, Italy, with a review of data for Italy
26. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders
27. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset
28. Delusional depression
29. Who benefits from tricyclic antidepressants: A survey
30. Serotonin transporter gene and risk for bipolar affective disorder: An association study in a Spanish population
31. Development of a rating scale for primary depressive illness
32. MIXREG: A computer program for mixed-effects regression analysis with autocorrelated errors
33. Allelic variation of human serotonin trasporter gene expression
34. Serotonin transporter (5-HTT) gene polymorphisms are not associated with susceptibility to mood disorders
35. Amitriptyline in depressive states
36. Depression, drugs, and delusions
37. Clinical and neuropsychological comparison of psychotic depression with nonpsychotic depression and schizophrenia
38. The validity of major depression with psychotic features based on a community study
39. Delusional depression: Natural history and response to treatment
40. Genetic linkage study of bipolar disorder and the serotonin transporter
41. Is a single tricyclic antidepressant trial an active treatment for psychotic depression?
42. Serotonin transporter gene polymorphism and antidepressant response
43. A rapid non-enzimatic method for the preparation of HMW DNA from blood for RFLP studies
44. Symptomatologic analysis of psychotic and non-psychotic depression
45. Best estimate of lifetime psychiatric diagnosis: A methodological study
46. Behavioral effects of tryptophan depletion in seasonal affective disorder associated with the serotonin transporter gene?
47. Association of anxiety-related traits with a polymorphismin the serotonin transporter gene regulatory region
48. Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor
49. Analysis of a novel functional polymorphism within the promoter region of the serotonin transporter gene (5-HTT) in Brazilian patients affected by bipolar disorder and schizophrenia
50. Late-life delusional depression
51. Pindolol augmentation of treatment-resistant depressed patients
52. Delusional unipolar depression: Description and drug response
53. Pharmacogenetic response to antidepressant in a multicase family with affective disorder
54. Antidepressant responses and segregation analyses in affective families
55. Association analysis of the 5-HT2C receptor and 5-HT transporter genes in bipolar disorder
56. Differentiation of two genetically specific types of depression by the response to antidepressant
57. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment
58. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius
59. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression
60. Are SSRI antidepressants a clinically homogeneous class of compounds?
61. Psychotic (delusional) major depression: Should it be included as a distinct syndrome in DSM-IV?
62. Depression
63. Mode of inheritance in mood disorders families according to fluvoxamine response
64. Clinical and demographical features of psychotic and nonpsychotic depression
65. Patterns of symptom improvement during antidepressant treatment of delusional depression
66. The search for genetic homogeneity in affective disorders
67. Outcomes on lithium treatment as a tool for genetic studies in affective disorders
68. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
69. Psychomotor symptoms of depression
70. No association between chromosome-18 markers and lithium-responsive affective disorders
71. How long should pindolol be associated with paroxetine to improve the antidepressant response?
72. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene
73. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study